Safety Reporting For OTCs Should Allow Targeted Risk Management – CHPA
This article was originally published in The Tan Sheet
Executive Summary
FDA ought to consider targeted questionnaires for specific types of suspected adverse drug reactions (SADRs) rather than an "active query" approach when dealing with OTC products, CHPA says
You may also be interested in...
FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says
FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says
FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says